Showing 17–28 of 28 results
Sclavo Free Protein S is a latex immunoassay (LIA) for the quantitative determination of Free Protein S in human citrated plasma. Protein S deficiency, either congenital or acquired, may lead to serious thrombotic events such as thrombophlebitis, deep vein thrombosis, or pulmonary embolism. A decrease in Protein S is associated with increased incidence of thromboembolism. The device can be used both with manual or automated methods. CONTAINS CALIBRATION PLASMA
Reagent for measurement of clotting time in human plasma.It is particularly suited to the monitoring of oral anticoagulant therapy and, in conjunction with the
appropriate factor deficient plasma, the measurement of factor activity in the extrinsic pathway. The reagent can be used manually or with an automated instrument.
Reagent for measurement of clotting time in human plasma.It is particularly suited to the monitoring of oral anticoagulant therapy and, in conjunction with the appropriate factor deficient plasma, the measurement of factor activity in the extrinsic pathway. The reagent can be used manually or with an automated instrument.
The Sclavo Immunodepleted Plasma Kits are intended for the quantitative determination of the respective factor in patients suspected of having a congenital or acquired deficiency of this coagulation protein. The device can be used both with manual or automated methods.
The Sclavo Immunodepleted Plasma Kits are intended for the quantitative determination of the respective factor in patients suspected of having a congenital or acquired deficiency of this coagulation protein. The device can be used both with manual or automated methods.
The Sclavo Immunodepleted Plasma Kits are intended for the quantitative determination of the respective factor in patients suspected of having a congenital or acquired deficiency of this coagulation protein. The device can be used both with manual or automated methods.
The Sclavo Immunodepleted Plasma Kits are intended for the quantitative determination of the respective factor in patients suspected of having a congenital or acquired deficiency of this coagulation protein. The device can be used both with manual or automated methods.
The Sclavo Immunodepleted Plasma Kits are intended for the quantitative determination of the respective factor in patients suspected of having a congenital or acquired deficiency of this coagulation protein. The device can be used both with manual or automated methods.
The Sclavo Immunodepleted Plasma Kits are intended for the quantitative determination of the respective factor in patients suspected of having a congenital or acquired deficiency of this coagulation protein. The device can be used both with manual or automated methods.
The Sclavo Immunodepleted Plasma Kits are intended for the quantitative determination of the respective factor in patients suspected of having a congenital or acquired deficiency of this coagulation protein. The device can be used both with manual or automated methods.
The Sclavo Immunodepleted Plasma Kits are intended for the quantitative determination of the respective factor in patients suspected of having a congenital or acquired deficiency of this coagulation protein. The device can be used both with manual or automated methods.
In vitro medical diagnostic device used fot the determination of Thrombin time. The reagent can be used manually or on semi-automated and automated instruments. The test is commonly applied to detect various sources of interference with normal blood
coagulation. Prolongation of the Thrombin clotting time can be taken as a qualitative indication of abnormal Fibrinogen levels (high or low), or the presence of interfering substances such as FDP?s or Heparin. Quantitative evaluation of the possible causes of prolonged Thrombin Time should be performed as follow-up studies, such as aPTT or chromogenic assay for Heparin, Clauss fibrinogen, FDdeterminations, heparin neutralisation by protamine sulphate or polybrene, normal plasma mixing studies or Reptilase
assay to distinguish between hypofibrinogenaemia and FDP effects.
